Xiaohua Lu
About Xiaohua Lu
Xiaohua Lu is the Director and Head of Bioanalytics, Clinical QC, Cell Therapy at Bristol Myers Squibb in Warren, NJ, with over 15 years of experience in cell therapy and bioanalytics.
Current Position at Bristol Myers Squibb
Xiaohua Lu serves as the Director and Head of Bioanalytics, Clinical QC in Cell Therapy at Bristol Myers Squibb. Operating in Warren, NJ, Lu oversees clinical quality control and bioanalytical processes, integral to the advancement of cell therapy products. With a direct responsibility for managing these critical aspects, Lu plays a key role in ensuring the efficacy and safety of innovative cell-based treatments.
Previous Experience at Bristol Myers Squibb and Celgene
Prior to their current role, Xiaohua Lu was the Associate Director, Clinical QC Bioanalytics, Cell Therapy at Bristol Myers Squibb from 2020 to 2022. Lu also held several significant roles at Celgene from 2007 to 2020. Notably, they served as Sr. Manager and Principal Bioengineer in Global MS&T for CAR T, Sr. Manager for CMC CAT T, and held various associate and senior scientist positions at Celgene Cellular Therapeutics.
Educational Background and Expertise
Xiaohua Lu earned a Ph.D. in Molecular Pathology from China Medical University. With over 15 years of expertise in cell therapy and bioanalytics, Lu's academic foundation has been critical to their professional success. This education has afforded them a comprehensive understanding of molecular pathology, directly contributing to their proficiency in clinical QC and bioanalytical method development.
Cell Therapy and CAR T Experience
Xiaohua Lu has extensive experience in the field of CAR T cell therapy. This includes their work on global manufacturing science and technology (MS&T) initiatives at Celgene. Throughout their various roles, Lu has consistently been involved in the advancement and application of CAR T technology, ensuring high standards for clinical quality control and bioanalytics.
Leadership in Bioanalytics and Clinical QC
Xiaohua Lu has a proven track record of leading teams in the biopharmaceutical industry. Transitioning from a scientific to a managerial role, Lu has demonstrated strong leadership capabilities in bioanalytics and clinical quality control. They have been instrumental in developing and implementing bioanalytical methods, ensuring the accuracy and reliability of QC processes for cell therapy products.